15

-46-

CLAIMS

What is claimed is:

1. A compound having the Formula I:

$$Y^{\mu} = (CX^{1}X^{2})_{n} - X$$

or a pharmaceutically acceptable salts thereof, wherein:

Y is
$$R^2 - N$$
 R^5 , or R^1 , or R^2

each n is independently 1 to 3 inclusive;

10 X^1 and X^2 are independently hydrogen or C_1 - C_8 alkyl, or -(CH₂)_y-Z; y is 0 to 4 inclusive;

Z is hydrogen, C₁-C₈ alkyl, C₃-C₈ cycloalkyl, C₁-C₈ perfluoroalkyl, C₂-C₈ alkenyl, phenyl, substituted phenyl, naphthyl, substituted naphthyl, -OH, -OC₁-C₈ alkyl, -SC₁-C₈ alkyl, -SO₃H, -CO₂H, -CO₂C₁-C₈ alkyl,

O O O O
$$\parallel$$
 \parallel \parallel -CHN₂, -CNH(C₁-C₈alkyl), -CN(C₁-C₈alkyl)₂, -NH₂, -NH(C₁-C₈alkyl),

 R^1 and R^2 are independently C_1 - C_8 alkyl or - $(CH_2)_n$ - C_3 - C_6 cycloalkyl, - $(CH_2)_n$ -phenyl, or R^1 and R^2 taken together with the nitrogen atom to which they are attached form a cyclic structure selected from

$$-N$$
 N
 R^3
 $CH_2)_m$
 R^4

$$\mathbb{R}^3$$
, or \mathbb{R}^3

10

where R^3 and R^4 independently are hydrogen, C_1 - C_8 alkyl, -(CH_2)_n-phenyl, or -(CH_2)_n cycloalkyl;

R⁵ is hydrogen, C₁-C₈ alkyl, halogen, or -CF₃;

each m is 2 to 8 inclusive;

O

0

15

20


10

15

20

25

30



wherein phenyl includes substituted phenyl.

- A compound in accordance with Claim 1 wherein
 R¹ is methyl, and R² is pentyl or hexyl.
- 3. A compound in accordance with Claim 1 wherein the R^1 group is R^2

located at the para position on the phenyl ring.

		4.	The compounds:
			(Z) 2-{5-[4-(Hexyl-methyl-amino)-benzylidene]-4-oxo-2-thioxo-
} -≛-			thiazolidin-3-yl}-ethanesulfonic acid;
	5		(Z) 2-{5-[4-(Hexyl-methyl-amino)-benzylidene]-4-oxo-2-thioxo-
			thiazolidin-3-yl}-ethanesulfonic acid methylamide;
			(Z) 2-{5-[4-(Hexyl-methyl-amino)-benzylidene]-4-oxo-2-thioxo-
			thiazolidin-3-yl}-ethanesulfonic acid trifluoroacetyl-amide;
			(Z) 2-{5-[4-(Hexyl-methyl-amino)-benzylidene]-4-oxo-2-thioxo-
			thiazolidi3-yl}-N-methyl-acetamide;
	10		(Z) N-({5-[4-(Hexyl-methyl-amino)-benzylidene]-4-oxo-2-thioxo-
C			thiazolidin-3-yl}-acetyl)-methanesulfonamide;
den und dem den fürst des fürst			(Z) N-{5-[4-(Dipentylamino-benzylidene)-4-oxo-2-thioxo-
U Li			thiazolidin-3-yl]-acetyl}-methanesulfonamide;
Ö			(Z) C,C,C-Trifluoro-N-({5-[4-(hexyl-methyl-amino)-benzylidene]-
\$	15		4-oxo-2-thioxo-thiazolidin-3-yl}-acetyl)-methanesulfonamide;
rate than the true and			(Z) N-{5-[4-(Dipentylamino-benzylidene)-4-oxo-2-thioxo-
C).			thiazolidin-3-yl]-acetyl}-C,C,C-trifluoro-methanesulfonamide;
Ü			(Z) N-(2-{5-[4-(hexyl-methyl-amino)-benzylidene]-4-oxo-2-
ļ.			thioxo-thiazolidin-3-yl}-acetyl)-benzenesulfonamide;
	20		(Z) N-(2-{5-[4-(Hexyl-methyl-amino)-benzylidene]-4-oxo-2-
			thioxo-thiazolin-3-yl}-ethyl)-methanesulfonamide;
			(Z) N-(2-{5-[4-(Hexyl-methyl-amino)-benzylidene]-4-oxo-2-
			thioxo-thiazolidin-3-yl}-ethyl)-benzenesulfonamide;
			(Z) C,C,C-Trifluoro-N-(2-{5-[4-(hexyl-methyl-amino)-
	25		benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-ethyl)-
			methanesulfonamide;
			(Z) 2,2,2-Trifluoro-N-(2-{5-[4-(hexyl-methyl-amino)-
			benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-ethyl)-acetamide;
	30		(Z) N-(2-{5-[4-Hexyl-methyl-amino)-benzylidene]-4-oxo-2-
			thioxo-thiazolidin-3-yl}ethyl)-acetamide;
			(Z) {5-[4-(Hexyl-methyl-amino)-benzylidene]-4-oxo-2-thioxo-
			thiazolidin-3-yl}-methanesulfonic acid;

-50-

	(Z) 5-[4-(Hexyl-methyl-amino)-benzylidene]-3-(1H-tetrazol-5-
	ylmethyl)-2-thioxo-thiazolidin-4-one;
	(Z) 5-(4-Dipentylamino-benzylidene)-3-(1H-tetrazol-5-ylmethyl)-
5	2-thioxo-thiazolidin-4-one;
	(Z) N-{[5-(4-Dibutylamino-benzylidene)-4-oxo-2-thioxo-
	thiazolidin-3-yl]-acetyl}-C,C,C-trifluoro-methanesulfonamide;
	(Z) N-{[5-(4-Dibutylamino-benzylidene)-4-oxo-2-thioxo-
	thiazolidin-3-yl]-acetyl}-benzenesulfonamide;
	(Z) 5-(4-Dibutylamino-benzylidene)-3-(1H-tetrazol-5-ylmethyl)-2-
10	thioxo-thiazolidin-4-one;
	(Z) N-{2-[5-(4-Dibutylamino-benzylidene)-4-oxo-2-thioxo-
	thiazolidin-3-yl]-acetyl}-methanesulfonamide;
	(Z) N-{2-[5-(4-Dipentylamino-benzylidene)-4-oxo-2-thioxo-
	thiazolidin-3-yl]-acetyl}-benzenesulfonamide;
15	(Z) 5-[(4aS,8aR)-4-(Octahydro-isoquinolin-2-yl)-benzylidene]-3-
	(1H-tetrazol-5-ylmethyl)-2-thioxo-thiazolidin-4-one;
	(Z) N-(2-{5-[(4aS,8aR)-4-(Octahydro-isoquinolin-2-yl)-
	benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetyl)-
	benzenesulfonamide;
20	(Z) N-{2-[5-(4-Dibutylamino-benzylidene)-4-oxo-2-thioxo-
	thiazolidin-3-yl]-acetyl}-4-fluoro-benzenesulfonamide;
	(Z) 2-[5-(4-Dibutylamino-benzylidene)-4-oxo-2-thioxo-thiazolidin-
	3-yl]-ethanesulfonic acid 4-fluoro-benzoylamide;
	(Z) N-{2-[5-(4-Dipentylamino-benzylidene)-4-oxo-2-thioxo-
25	thiazolidin-3-yl]-acetyl}-4-fluoro-benzenesulfonamide;
	(Z) 2-[5-(4-Dibutylamino-benzylidene)-4-oxo-2-thioxo-thiazolidin-
	3-yl]-ethanesulfonic acid benzoylamide;
	(Z) 2-{5-[4-(Octahydro-isoquinolin-2-yl)-benzylidene]-4-oxo-2-
	thioxo-thiazolidin-3-yl}-ethanesulfonic acid benzoylamide;
30	(Z) 2-{5-[4-(Octahydro-isoquinolin-2-yl)-benzylidene]-4-oxo-2-
	thioxo-thiazolidin-3-yl}-ethanesulfonic acid 4-fluoro-benzoylamide;
	(Z) 2-[5-(4-Dipentylamino-benzylidene)-4-oxo-2-thioxo-
	thiazolidin-3-yl]-ethanesulfonic acid 4-fluoro-benzoylamide;
	10 15 20 25

10

15

20

25

-51-
(Z) 3-(5-Hydroxy-4-oxo-4H-pyran-2-ylmethyl)-5-[4-(octahydro-
isoquinolin-2-yl)-benzylidene]-2-thioxo-thiazolidin-4-one;
(Z) 5-(4-Dibutylamino-benzylidene)-3-(5-hydroxy-4-oxo-4H-
pyran-2-ylmethyl)-2-thioxo-thiazolidin-4-one;
(Z) 3-(5-Hydroxy-4-oxo-4H-pyran-2-ylmethyl)-5-[4-(4-propyl-
piperidin-1-yl)-benzylidene]-2-thioxo-thiazolidin-4-one;
(Z) 5-[4[(4-Propyl-piperidin-1-yl)-benzylidene]-3-(1H-tetrazol-5-
ylmethyl)-2-thioxo-thiazolidin-4-one;
(Z) N-(2-{4-Oxo-5-[4-(4-propyl-piperidin-1-yl)-benzylidene]-2-
thioxo-thiazolidin-3-yl}-acetyl)-benzenesulfonamide;
(Z) N-(2-{4-Oxo-5-[4-(4-propyl-piperidin-1-yl)-benzylidene]-2-
thioxo-thiazolidin-3-yl}-acetyl)-methanesulfonamide;
(Z) 4-Fluoro-N-(2-{5-[(4aS,8aR)-4-(octahydro-isoquinolin-2-yl)-
benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetyl)-
benzenesulfonamide;
(Z) 4-Fluoro-N-(2-{4-oxo-5-[4-(4-propyl-piperidin-1-yl)-
benzylidene]-2-thioxo-thiazolidin-3-yl}-acetyl)-benzenesulfonamide;
(Z) 2-[5-(4-Hexyl-methyl-amino-benzylidene)-4-oxo-2-thioxo-
thiazolidin-3-yl]-ethanesulfonic acid 4-fluoro-benzoylamide;
(Z) N-({5-[4[(Octahydro-isoquinolin-2-yl)-benzylidene]-4-oxo-2-
thioxo-thiazolidin-3-yl}-acetyl)-methanesulfonamide;
(Z) N-({5-[4[(Octahydro-isoquinolin-2-yl)-benzylidene]-4-oxo-2-
thioxo-thiazolidin-3-yl}-acetyl)-C,C,C-trifluoro-methanesulfonamide;
(Z) N-(2-{4-Oxo-5-[4-(4-propyl-piperidin-1-yl)-benzylidene]-2-
thioxo-thiazolidin-3-yl}-acetyl)-C,C,C-trifluoro-methanesulfonamide;
(Z) 2-[5-(4-Dibutylamino-benzylidene)-4-oxo-2-thioxo-thiazolidin
3-yl]-ethanesulfonic acid methylamide;
(Z) 2-[5-(4-Dipentylamino-benzylidene)-4-oxo-2-thioxo-
thiazolidin-3-yl]-ethanesulfonic acid methylamide;
(7) 2-[5-(4-Hexyl-methyl-amino-benzylidene)-4-oxo-2-thioxo-

thiazolidin-3-yl]-ethanesulfonic acid methylamide;

thioxo-thiazolidin-3-yl}-ethanesulfonic acid methylamide;

(Z) N-2-{4-Oxo-5-[4-(4-propyl-piperidin-1-yl)-benzylidene]-2-

30



-52-

		(Z) 2-{5-[4-(octahydro-isoquinolin-2-yl)-benzylidene]-4-oxo-2-
		thioxo-thiazolidin-3-yl}S-ethanesulfonic acid methylamide;
		(Z) 2-{5-[4-(Octahydro-isoquinolin-2-yl)-benzylidene]-4-oxo-2-
the transfer that the last that the last the las		thioxo-thiazolidin-3-yl}S-ethanesulfonic acid trifluoroacetylamide;
	5	(Z) N-2-{4-Oxo-5-[4-(4-propyl-piperidin-1-yl)-benzylidene]-2-
		thioxo-thiazolidin-3-yl}-ethanesulfonic acid trifluoroacetylamide;
		(Z) 2-[5-(4-Dipentylamino-benzylidene)-4-oxo-2-thioxo-
		thiazolidin-3-yl]-ethanesulfonic acid trifluoroacetylamide;
		(Z) 2-[5-(4-Dibutylamino-benzylidene)-4-oxo-2-thioxo-thiazolidin-
	10	3-yl]-ethanesulfonic acid trifluoroacetylamide;
		(Z) 2-[5-(4-Dipentylamino-benzylidene)-4-oxo-2-thioxo-
		thiazolidin-3-yl]-ethanesulfonic acid benzoylamide;
		(Z) 2-[5-(4-Hexyl-methyl-benzylidene)-4-oxo-2-thioxo-thiazolidin-
jj T		3-yl]-ethanesulfonic acid benzoylamide;
The first disc first time of a first	15	(Z) N-2-{4-Oxo-5-[4-(4-propyl-piperidin-1-yl)-benzylidene]-2-
		thioxo-thiazolidin-3-yl}-ethanesulfonic acid benzoylamide;
		(Z) N-2-{4-Oxo-5-[4-(4-propyl-piperidin-1-yl)-benzylidene]-2-
*		thioxo-thiazolidin-3-yl}-ethanesulfonic acid 4-fluoro-benzoylamide;
=::} ===		(Z) 2-[5-(4-Hexyl-methyl-benzylidene)-4-oxo-2-thioxo-thiazolidin-
	20	3-yl]-ethanesulfonic acid 4-fluoro-benzoylamide;
		(Z) [5-(4-Hexyl-methyl-amino)-benzylidene]-3-(5-oxo-4,5-
		dihydro-[1,2,4]oxadiazol-3-ylmethyl)-2-thioxo-thiazolidin-4one;
		(Z) [5-(4-Propyl-piperidin-1-yl)-benzylidene]-3-(5-oxo-4,5-
		dihydro-[1,2,4]oxadiazol-3-ylmethyl)-2-thioxo-thiazolidin-4one;
	25	(Z) [5-(4-Octahydro-isoquinolin-2-yl)-benzylidene]-3-(5-oxo-4,5-
		dihydro-[1,2,4]oxadiazol-3-ylmethyl)-2-thioxo-thiazolidin-4one;
		(Z) 5-(4-Dipentylamino-benzylidene)-3-(5-oxo-4,5-dihydro-
		[1,2,4]oxadiazol-3-ylmethyl)-2-thioxo-thiazolidin-4-one; or
		(Z) 5-(4-Dibutylamino-benzylidene)-3-(5-oxo-4,5-dihydro-
	30	[1,2,4]oxadiazol-3-ylmethyl)-2-thioxo-thiazolidin-4-one.

A pharmaceutical composition comprising a compound of Claim 1. 5.

*** A

5

10

15



6. A method of treating Alzheimer's disease, the method comprising administering to a patient having Alzheimer's disease a therapeutically effective amount of a compound of Claim 1.

-53-

- 7. A method of inhibiting the aggregation of amyloid proteins to form amyloid deposits, the method comprising administering to a patient in need of inhibition of the aggregation of amyloid proteins an amyloid protein aggregation inhibiting amount of a compound of Claim 1.
- 8. A method of imaging amyloid deposits, the method comprising the steps of:
 - a. introducing into a patient a detectable quantity of a labeled compound of Claim 1;
 - b. allowing sufficient time for the labeled compound to become associated with amyloid deposits; and
 - c. detecting the labeled compound associated with the amyloid deposits.
- 9. The method of Claim 8 wherein the patient has or is suspected to have Alzheimer's disease.
- 10. The method of Claim 8 wherein the labeled compound is a radiolabeled compound.
- The method of Claim 8 herein the labeled compound is detected using MRI.